On December 1, 2021 Accro Bioscience (Suzhou) Limited ("Accropeutics Bioscience"), a China-based leadingbiotechnology company, reported that the company has recently raised over $50 million in an oversubscribed Series B round (Press release, Accro Bioscience, DEC 1, 2021, View Source [SID1234632773]). The financing was led by HongtaiAplus with participation from South China Venture Capital, Shenzhen Capital Group, Suzhou Oriza Holdings, and others.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Accropeutics Bioscience will leverage the funds to advance clinical development, pre-clinical research and international partnerships," said Dr. Xiaohu Zhang, co-founder and CEO of Accropeutics Bioscience, "We are very pleased with the support and confidence of our current and new investors."

"We appreciate the R&D and execution capabilities of the team, and look forward to the continuous breakthroughs of Accropeutics Bioscience in the future," said Morningside.

"We are optimistic about the development of Accropeutics Bioscience," said HongtaiAplus, "We are delighted to lead this round of financing and look forward to the in-depth cooperation with Accropeutics Bioscience in the future."

On December 1, 2021 Molecular Targeting Technologies, Inc. (MTTI) and Evergreen Theragnostics, Inc., reported an agreement in which Evergreen will manufacture MTTI’s EvaThera platform of radiopharmaceuticals (Press release, Molecular Targeting Technologies, DEC 1, 2021, View Source [SID1234632260]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The EvaThera platform is a new generation of Evans blue-based molecules with strong affinity for albumin, which extends the blood half-life of the radiopharmaceutical, potentially leading to improved outcomes. MTTI’s leading pipeline candidates are both Lu-177 based radiotherapeutics: EBTATE, targeting neuroendocrine and other SSTR2 expressing tumors, and EBRGD, targeting integrin expressing cancers like glioblastoma multiforme.

"The Evergreen team brings deep experience in manufacturing and nationwide distribution of Lu-177 products. This agreement is key to a robust and reliable supply in North America for our upcoming clinical trials and beyond," said Chris Pak, President & CEO of MTTI.

Evergreen will manufacture MTTI clinical supplies from its newly commissioned facility in Springfield, NJ and will leverage the team’s broad experience with Lu-177 based radiotherapeutics by providing comprehensive supply chain management from isotope sourcing to drug delivery at the clinical trial site.

"We are very pleased to support MTTI by providing quality GMP manufacturing for their very promising platform of products. The technology behind the EvaThera platform has the potential to make a meaningful improvement in the lives of patients," said James Cook, President & CEO of Evergreen.

On December 1, 2021 Propella Therapeutics, Inc. reported that Presented at the MedInvest Oncology Conference on December 7, 2021 (Press release, Propella Therapeutics, DEC 1, 2021, https://propellatx.com/2021/12/01/presentation-forthcoming-medinvest-oncology-conference-december-7-10-2021/ [SID1234596636]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 1, 2021 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported it will host a virtual Investor Day on Wednesday, December 8, 2021 from 10:00 a.m. to 12:30 p.m. ET (Press release, Karyopharm, DEC 1, 2021, View Source,-2021 [SID1234596382]). Karyopharm’s executive management team will be joined by six recognized thought leaders in multiple myeloma, gynecological malignancies, myelodysplastic syndromes and myelofibrosis, including:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rafael Fonseca, MD, Mayo Clinic
Cristina Gasparetto, MD, Duke University Medical Center
Vicky Makker, MD, Memorial Sloan Kettering Cancer Center
Robert Coleman, MD, US Oncology Research
Guillermo Garcia-Manero, MD, MD Anderson Cancer Center
Srinivas Tantravahi, MBBS, MRCP, University of Utah
The virtual event will outline the Company’s commercial opportunities, refined corporate vision, pipeline priorities and corporate milestones that will support Karyopharm’s continued evolution toward a sustainable, fully-integrated development and commercialization organization.

To access the event, please dial (833) 989-2978 (local) or (236) 714-4042 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live video webcast of the event will be available under "Events & Presentations" in the Investor section of the Company’s website, View Source An archived webcast will be available on the Company’s website approximately two hours after the event.

On December 1, 2021 Eli Lilly and Company (NYSE: LLY) reported that it will host a meeting for the investment community on Wednesday, Dec. 15, 2021, from 9 a.m. to 4 p.m., Eastern time (Press release, Eli Lilly, DEC 1, 2021, View Source [SID1234596381]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Earlier that day, the company will announce its initial financial guidance for 2022, and at the meeting, Lilly leadership will further detail the 2022 financial guidance. A substantial portion of the meeting will cover Lilly’s research and development opportunities, with a focus on the early-phase pipeline, in the areas of diabetes, immunology, neuroscience and oncology.

In-person attendance is by invitation only and advance registration is required. Investors, media and the general public can access a live video webcast through a link that will be posted on Lilly’s website at View Source A replay of the presentation will be available on the website following the meeting.